The latest edition shows that, depending on the patients' country of residence, doctors would be able to prescribe between 39% and 86% of the new medicines with a valid EU marketing authorisation granted between 1 January 2007 and 31 December 2009. For those new medicines that doctors can prescribe under the national healthcare provisions, average time elapsing between the date of EU market authorisation and the "accessibility" date in 14 European countries will vary from 88 to 392 days.

Executive Summary of the Report 2010